Q1 2012 venture financing round-up: ortho bucks investment trend and overtakes heart firms
This article was originally published in Clinica
Executive Summary
The arid, post-credit crunch IPO market may be on its way to becoming a hazy memory as the flow of successful medtech floats look to be strengthening as we move well into the first half of 2012. Already, there has been the €38m ($49.6m) flotation of orthopaedics imaging specialist EOS Imaging on the EuroNext (www.clinica.co.uk, 17 February 2012), while Osprey Medical raised Aus$20 ($21m) in its IPO on the Australian Stock Exchange (www.clinica.co.uk, 19 April 2012). There are even more ambitious flotations in the pipeline, such as spinal implant firm Globus's plans to raise $100m in an IPO on the NYSE (www.clinica.co.uk, 2 April 2012) while just this week (7 May), cancer diagnostics firm Cancer Genetics announced it was looking to bag around $48m from its planned IPO on the Nasdaq.